MBX

MBX Biosciences, Inc.
CAPPED RATING

MBX Biosciences, Inc. (MBX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -12.7
EV / EBITDA -13.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -20.5%
Price Return 12M 118.8%
Catalyst Signal 0.00
Market Cap $2.7B
TTM Revenue N/A
Price / Sales N/A
ROE -33.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D (1.4) C+ (2.8) B- (3.1) C+ (2.6) C (2.5)
2026-11-06 C+ (2.5) D (1.3) C+ (2.8) B (3.3) C+ (2.7) C+ (2.5)
2026-10-30 C+ (2.5) D (1.3) C+ (2.8) B (3.4) C+ (2.7) C+ (2.5)
2026-10-23 C+ (2.5) D (1.3) C+ (2.8) B (3.3) C+ (2.6) C+ (2.5)
2026-10-16 C+ (2.5) D (1.3) C+ (2.8) B (3.3) C+ (2.6) C+ (2.5)
Page 1 of 4